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Abstract
Objective: Hematocrit (HCT)/hemoglobin (Hb) ratio in (%/g/dL) is around 3, with high fidelity between mea-
sured and derived Hb (applying the conversion using HCT) in various pathologies. We examined changes in
HCT and Hb values and HCT/Hb, compared with baseline, in men with adult-onset testosterone deficiency
(TD) given testosterone therapy (TTh).
Materials and Methods: Data were analyzed from an observational, prospective registry study at various time
points in 353 men with adult-onset TD receiving testosterone undecanoate (median follow-up: 105 months).
After establishing baseline HCT/Hb, we compared (cf. baseline) changes in HCT, Hb, and HCT/Hb at 12, 48, 72,
and 96 months. Regression analyses determined predictors of HCT and Hb change.
Results: TTh was associated with ( p < 0.0001) increases in median HCT and Hb; 44% to 49% and 14.5 to 14.9 g/dL
at final assessment, respectively. Regression analyses showed that HCT change was associated with baseline HCT
and testosterone levels, while Hb change was associated with baseline Hb, HCT, and testosterone levels. In the
total cohort and subgroups, HCT/Hb increased significantly at all time points ( p < 0.0001, cf. baseline) with over
90% of men demonstrating increases. Linear regression showed that the ratio of HCT change/Hb change (i.e.,
difference between HCT at the various time points and baseline value/difference between Hb at the various
time points and baseline value), following TTh at each time point was higher than the baseline HCT/Hb ratio.
Conclusion: HCT increase was greater than we anticipated from the established HCT/Hb of 3. We speculate that
increased erythrocyte life span with associated higher Hb loss via vesiculation could account for our observation.
This could have a bearing when using HbA1c as an indicator in men with adult-onset TD on TTh.
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Introduction
Adult-onset testosterone deficiency (TD) is defined by
low serum testosterone levels and associated symptoms
and signs.1 The condition is common, with a prevalence
of 6–12% in the general male population and even higher
at 40% in men with type 2 diabetes (T2DM).2,3 A meta-
analysis of pooled observational studies demonstrated
increased all-cause and cardiovascular mortality in
men with adult-onset TD.4 Longitudinal studies by Mur-
aleedharan et al.5 and Hackett et al.,6,7 having demon-
strated increased mortality in men with T2DM and
low serum testosterone, showed a reduction in all-
cause mortality following testosterone therapy (TTh).
A few studies8–10 have suggested increased TTh-
associated cardiovascular disease (CVD) and, despite
the methodology being criticized,11 organizations such
as the U.S. Food and Drug Administration have
expressed concerns.12 Reassuringly, a meta-analysis of
interventional studies concluded that appropriate TTh
was not associated with increased risk of CVD, and in
some subpopulations, a beneficial effect was possible.13
Thus, guidelines by the British Society for Sexual Medi-
cine3 and International Society for Sexual Medicine14
suggest that men with a serum total testosterone (TT)
<8 nmol/L or free testosterone <0.180 nmol/L usually re-
quire TTh, while men with serum TT between 8 and
12 nmol/L may, depending on symptoms, be considered
for a TTh trial.
Despite the accumulating safety data,11,13 it is impor-
tant that vigilance is maintained, especially for factors
associated with CVD. This must be extended to sub-
groups as heterogeneity may be evident in adult-onset
TD.15 An elevated hematocrit (HCT) appears the most
frequent adverse effect of TTh.16,17 The relationship be-
tween HCT, atherogenesis, and mortality is not well
understood, with many conflicting studies.18–23 Interest-
ingly, one of these showed a U-shaped association
between HCT and mortality, suggesting a complex non-
linear relationship.22 Currently, monitoring of HCT is
recommended during TTh, with guidelines setting dif-
fering HCT thresholds (50–54%) above which change
in management is recommended.1,3,24–26
The mechanism of testosterone-induced erythrocy-
tosis has not been fully elucidated. While some early
studies suggested indirect bone marrow action via
erythropoietin activity,27,28 these findings have not al-
ways been evident.29 A more recent study in 2016 by
Dhindsa et al. showed that TTh in men with hypogona-
dotropic hypogonadism increased HCT and this was
associated with a rise in erythropoietin, expression of
ferroportin and transferrin receptor-2, as well as sup-
pression of hepcidin.30 Testosterone leading to direct
stimulation of bone marrow erythroblast synthesis
and iron incorporation into the erythroblasts via circu-
lating soluble transferrin receptor (sTfr), which is in-
volved in the intracellular transport of iron and chiefly
found within erythroblasts, have also been considered
as possible mechanisms.31–33 However, Coviello et al.
were unable to demonstrate sTfr correlating with testos-
terone levels.29
Another putative mechanism for the observed eryth-
rocyte increase associated with TTh could arise from a
decrease in degradation. Following TTh, changes in
lipid membrane composition of the erythrocyte have
been observed, thereby perhaps enhancing erythrocyte
flexibility and thus survival.34 Interestingly, in healthy
subjects, about 20% of erythrocyte hemoglobin (Hb)
appears to be shed via vesiculation, a phenomenon
that increases during the second half of the erythrocyte
life span.35,36 Thus, in the event of increased erythrocyte
life span with a consequent greater Hb loss, an increased
HCT/Hb ratio may be expected. In most individuals, the
HCT (percentage) appears about three times the Hb
(g/dL), with high fidelity between measured and derived
(from HCT) Hb values.36 Furthermore, sensitivity, spec-
ificity, and positive predictive values (except in anemia)
remained high, irrespective of age, gender, renal func-
tion, and hydration status.37–39
In this analysis, we aim to characterize Hb and
HCT changes (absolute values and the ratio) associ-
ated with TTh in men with adult-onset TD, using
data from an observational registry study40 at various
time points (0, 12, 48, 72, and 96 months). First, the
aim was to report changes in HCT and Hb, and sec-
ond, to examine the HCT/Hb ratio at each time point
(in the total cohort and in subgroup-stratified base-
line characteristics).
Materials and Methods
The data used were from an observational, prospective,
cumulative registry study40 of 353 men [median age
(IQR): 60.0 (55.0, 64.0), median follow-up (IQR): 105
(78, 141) months] with adult-onset TD (serum TT
£12.1 nmol/L) given testosterone undecanoate (TU)
1000 mg/12 weeks following an initial 6-week interval).
Data were collected at a minimum of 6-month inter-
vals. The database also contained 384 men [median
age (IQR): 64.0 (60.0, 67.0), median follow-up (IQR):
114 (96, 126) months] who opted against TTh due to
financial constraints and/or negative perceptions of
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TTh. The main analyses studied changes in HCT, Hb,
and HCT/Hb ratios after 12 (353 men), 48 (313 men),
72 (279 men), and 96 (207 men) months of TTh with
the number of patients decreasing in view of the
study design. The baseline characteristics of the 353
men commenced on TU are shown in Table 1 and foot-
notes. The German Medical Association’s ethical
guidelines for observational studies were adhered to
with every participant consenting to be included and
having his data analyzed. Following review, ethics com-
mittees in Germany and England stated that formal ap-
proval was not required. Institutional review board
statement for University Hospitals Birmingham was
received.
Serum TT (trough) levels were measured using an
immunoassay (Abbott Architect). Hb levels were
checked using photometry (CELL DYN Ruby/Abbott)
and HCT was estimated using Microhematocrit
(Mindray 3000 Plus).
Statistical methods
The baseline HCT and Hb values were not normally
distributed with both skewness and kurtosis evident
( p < 0.0001 when considered in combination), hence
nonparametric tests were used to compare changes in
HCT, Hb values, and HCT/Hb ratios between baseline
and fixed time points during treatment. Sign-rank tests
were carried out to compare changes in HCT and Hb
values between baseline and at fixed time points during
treatment. Factors associated with change in HCT and
Hb during follow-up were studied using multiple re-
gression. HCT/Hb ratios were calculated for each indi-
vidual, and changes between the baseline values and
those obtained after 12, 48, 72, and 96 months of
TTh were compared using sign-rank tests. Finally, the
associations between (1) baseline HCT and Hb, and
(2) changes in HCT and changes in Hb were studied
using linear regression, with scatterplots with trend
lines visually reinforcing the findings.
Results
Table 1 shows that serum TT levels increased ( p <
0.0001, sign-rank test) from baseline (median:
10.05 nmol/L) to 16.64, 16.99, 15.95, 16.99, and
18.72 nmol/L at 12, 48, 72, 96 months, and final assess-
ment, respectively, in the men receiving TTh. In the
men not receiving TTh, median serum TT was 9.71
and 8.32 nmol/L at baseline and final assessment, re-
spectively. HCT or Hb did not increase during follow-
up in the 384 men not opting for TTh; median (IQR)
HCT = 46 (45–47) % and median (IQR) Hb = 14.7
(14.3–15.1) g/dL at baseline; median (IQR) HCT = 46
(45–47) % and median (IQR) Hb = 14.5 (14.2–15.0)
g/dL at final assessment. In contrast, TTh was associ-
ated with an increase ( p < 0.0001, sign-rank test) in
both HCT and Hb values in the 353 treated men;
Table 1. Hematocrit and hemoglobin values at baseline and fixed time points (12, 48, 72, and 96 months
of testosterone therapy) in the total cohort and subgroups stratified by smoking and type 2 diabetes
Pre-TTh 12 months TTh 48 months TTh 72 months TTh 96 months TTh
Median (IQR)
Total cohort, n 353 353 313 279 207
TT (nmol/L) 10.05 (9.36–10.75) 16.64 (14.91–19.07) 16.99 (15.94–19.07) 15.95 (14.91–17.68) 16.99 (15.95–18.38)
Hb (g/dL) 14.5 (14.1–14.9) 14.7 (14.3–15.3) 14.8 (14.6–15.3) 14.9 (14.6–15.3) 15.1 (14.7–15.3)
HCT (%) 44 (43–46) 46 (45–48) 48 (47–49) 48 (47–49) 48 (47–49)
Cohort categorized by baseline characteristics
Current smokers, n 135 135 119 103 88
Hb (g/dL) 14.6 (14.2–15.1) 14.9 (14.5–15.4) 15.0 (14.6–15.3) 15.1 (14.7–15.3) 15.2 (14.7–15.4)
HCT (%) 44 (43–45) 47 (45–49) 48 (47–49) 48 (47–49) 48 (47–49)
Nonsmokers, n 218 218 194 176 119
Hb (g/dL) 14.5 (14.1–14.8) 14.7 (14.3–15.2) 14.8 (14.6–15.3) 14.8 (14.6–15.3) 15.0 (14.7–15.3)
HCT (%) 44 (43–46) 46 (45–48) 48 (47–49) 48 (47–49) 48 (47–48)
Men with T2DM, n 148 148 121 100 74
Hb (g/dL) 14.6 (14.2–14.9) 14.8 (14.5–15.3) 14.9 (14.7–15.3) 15.0 (14.7–15.3) 15.2 (14.8–15.3)
HCT (%) 45 (44–46) 46 (45–48) 48 (47–49) 48 (47–49) 48 (47–49)
Men without T2DM, n 205 205 192 179 133
Hb (g/dL) 14.3 (14.1–14.8) 14.7 (14.3–15.3) 14.8 (14.5–15.2) 14.8 (14.5–15.3) 15.0 (14.6–15.3)
HCT (%) 44 (42–45) 46 (44–48) 48 (47–49) 48 (47–49) 48 (47–49)
Baseline characteristics of the 353 men not shown in the above table; median (IQR). Age: 60 (55, 64) years, follow-up: 105 (78, 141) months. Waist
circumference: 108 (100, 114) cm. Serum TT: 10.05 (9.36, 10.75) nmol/L. HbA1c: 8.15 (5.8, 8.9)%, total cholesterol: 7.7 (7.2, 8.6) mmol/L, triglycerides: 3.2
(2.8, 3.5) mmol/L. Systolic blood pressure: 158 (141, 167) mmHg, diastolic blood pressure: 94 (83, 98) mmHg.
Hb, hemoglobin; HCT, hematocrit; T2DM, type 2 diabetes; TT, total testosterone; TTh, testosterone therapy.
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median (IQR) HCT = 44 (43–46) % and median (IQR)
Hb = 14.5 (14.1–14.9) g/dL at baseline; median (IQR)
HCT = 49 (48–50) % and median (IQR) Hb = 14.9
(14.7–15.3) g/dL at final assessment. Table 1 demon-
strates HCT and Hb levels at baseline and the fixed
time points during follow-up in the total cohort on
TTh, as well as subgroups based on baseline character-
istics (smoking status and T2DM). Both HCT and Hb
increased significantly at each time point ( p < 0.0001,
sign-rank test) compared with baseline in the total co-
hort as well as subgroups.
Separate multiple regression analyses showed that
change in HCT at final assessment was associated
with baseline HCT (coefficient [c] =0.95, 95% confi-
dence intervals [CI] =1.05 to 0.87, p < 0.001) and
baseline TT (c =0.11, 95% CI =0.21 to 0.016,
p = 0.023), while change in Hb at final assessment was
associated with baseline Hb (c =0.53, 95% CI =
0.60 to 0.46, p < 0.001), baseline HCT (c = 0.021,
95% CI =0.40 to 0.0018, p = 0.032), baseline TT
(c =0.026, 95% CI =0.048 to 0.0043, p = 0.019),
and follow-up (c = 0.0035, 95% CI = 0.0025–0.0044,
p < 0.001). Age, smoking status, and T2DM were not
associated with change in either HCT or Hb.
Table 2 shows the median calculated HCT/Hb ratio
in the total cohort and subgroups (stratified by median
baseline age, Hb, HCT, serum TT, as well as smoking
and diabetes status). The baseline HCT/Hb ratio was
3.03 in the total cohort. The HCT/Hb ratio increased
significantly ( p < 0.0001, sign-rank test) at every time
point (sign-rank test, p < 0.0001) compared with base-
line in the total cohort of men on TTh and all the sub-
groups (Table 2). Table 2 also presents the number
(and %) of men with increasing and decreasing
HCT/Hb ratio. After 48, 72, and 96 months of TTh,
>90% of men had an increasing HCT/Hb ratio.
We now wish to confirm the increased HCT/Hb
ratio during TTh by studying the association between
the change in HCT and change in Hb. A scatter plot
demonstrating the association between baseline HCT
and Hb (c = 3.03, 95% CI = 2.75–3.31) is shown
(Fig. 1). We then determined the association between
change in HCT and change in Hb after 48 (Fig. 2),
72, and 96 months of TTh (12-month follow-up data
were omitted as the HCT continued to rise after that
time point). Figure 2 (footnote table) shows the results
of the linear regression; the c and intercept values were
higher than those obtained from the linear regression
between baseline HCT and Hb, with no overlap be-
tween the 95% CI seen in Figure 1 (footnote table).
These data and plots reinforce the findings presented
in Table 2: an increase in the HCT/Hb ratio occurs in
men with adult-onset TD on TTh.
Although we focused on the HCT/Hb ratio following
TTh, we also had data on the 384 men who opted
against TTh. The median HCT remained 48% at all
time points studied [baseline (384 men), 12 months
(383 men), 48 months (367 men), 72 months (342
men), 96 months (283 men), and final assessment].
Interestingly there was a slight reduction in Hb during
follow-up: 14.7 g/dL (baseline), 14.7 g/dL (12 months),
14.6 g/dL (48 months), 14.6 g/dL (72 months),
14.6 g/dL (96 months), and 14.5 g/dL (final assess-
ment). Thus, unlike in the cohort on TTh where both
HCT and Hb increased at all time points, in the men
opting against TTh, any change in the median
HCT/Hb ratios appeared driven by changes in Hb:
3.13 (baseline), 3.13 (12 months), 3.13 (48 months),
3.11 (72 months), 3.15 (96 months), and 3.16 (final as-
sessment). As the baseline characteristics of the cohorts
(men on TTh and men opting against TTh) varied, we
avoided intercohort comparisons.
Discussion
In this study, we characterized the changes in HCT and
Hb associated with TTh (TU) in men with adult-onset
TD. At the final assessment, median HCT and Hb in-
creased 5% and 0.4 g/dL, respectively. We also pre-
sented the changes in HCT and Hb at fixed time
points (12, 48, 72, and 96 months) with the changes
appearing to plateau after 48 months of treatment.
The HCT/Hb ratio of 3.03 at baseline (Table 2 and
Fig. 1) was similar to the numeral 3.0 that is often
quoted in the literature.37–39 However, while on TTh,
the HCT/Hb ratio significantly increased with the ra-
tios increasing in >90% of men on TTh for 48, 72,
and 96 months. The change in HCT/change in Hb
ratio was also significantly greater while on TTh
(Fig. 2).
Studies determining the long-term effects of TTh on
both HCT and Hb are scarce. Wang et al. studied HCT
and Hb concentrations in 123 men after 36 months of
treatment with long-term testosterone gel.41 HCT and
Hb levels appeared to show a dose-related increase over
12 months before plateauing. Aversa et al. showed in an
randomized-controlled trial (RCT) that TU (40 men
with the metabolic syndrome or adult-onset TD) led
to HCT and Hb increases after 12 and 24 months.
HCT and Hb increased from baseline figures of
44.0 – 3.0% and 14.9 – 1.2 g/dL by 3.5 – 3.0% and



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.4 – 1.05 g/dL (12 months) and 3.1 – 3.5% and
0.3 – 1.1 g/dL (24 months), respectively.42 The results
after 24 months are similar to our results. We showed a
similar pattern after 12, 48, 72, and 96 months, an in-
crease in HCT being a common effect of TU.42
An increase in erythropoiesis is a possible mecha-
nism for the increased HCT and Hb. This could
occur with increased erythropoietin and/or direct stim-
ulation of bone marrow erythroblasts, as well as iron
incorporation into erythrocytes.27,28,31–33 Lundby
et al. treated eight healthy subjects with baseline HCT
of 42.0% – 3.0% and Hb of 14.2 – 6.2 g/dL with erythro-
poietin, which stimulates the erythroid precursor cells
located in the bone marrow.43 After 12 weeks of treat-
ment, the HCT and Hb concentrations increased to
49.0% – 3.0% and 17.1 – 5.1 g/dL.43 Their observed in-
crease in Hb in comparison with HCT in this situation
appears much higher than our own study observations,
although subjects were given supplemental iron before
and throughout follow-up, which may have influenced
outcomes. The role of the androgen receptor CAG re-
peat polymorphism in mediating TTh-associated HCT
change was studied by Stanworth et al. in the TIMES2
substudy.44 It was noted that neither androgen CAG
repeats nor change in serum TT levels was associated
with change in HCT. Interestingly, in contrast to our
findings, baseline HCT appeared positively correlated
with change in HCT.44 We cannot explain the varied
findings observed; even after 12 months of follow-up
(as in the TIMES2 study), the association between
change in HCT and baseline HCT was negative
(c =0.63, 95% CI =0.72 to 0.53, p < 0.001,
n = 346). It must also be stated that changes in fluid sta-
tus (5 cases of peripheral edema in the 23 men experi-
encing adverse cardiovascular events that led to the
trial being discontinued prematurely) in men on
TTh, as suggested by the Testosterone in Older Men
with Mobility Limitations (TOM) trial, do not provide
an explanation for the changes in HCT, Hb, and
HCT/Hb ratio seen in our study following TTh.8
Our results suggest that the association between TTh
and increased HCT and Hb, in addition to erythropoi-
esis, may also be mediated by other mechanisms. One
mechanism could involve an increase in the life span
of the erythrocyte associated with TTh in men with
adult-onset TD. Erythrocytes are usually destroyed by
macrocytes via erythrophagocytosis in the splenic and
hepatic sinusoids after around 120 days, although var-
iation in this duration can occur.45 It has been sug-
gested that oxidative stress, by damaging the cell
FIG. 1. A scatter plot and trend line
demonstrating the association between HCT
and Hb at baseline. HCT, hematocrit; Hb,
hemoglobin.
FIG. 2. A scatter plot and trend line
demonstrating the association between change
in HCT and Hb after 48 months of TTh. TTh,
testosterone therapy.
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membrane and cytoplasm of the erythrocyte, shortens
life span.46,47 However, mechanisms such as eryptosis
(considered a suicidal cell death due to hyperosmolar-
ity, oxidative stress, and exposure to xenobiotics) may
occur, although earlier than erythrophagocytosis.48
The process of erythrophagocytosis appears mediated
by a dynamic balance between phosphatidylserine
(prophagocytic)45 on the inner layer of the cell mem-
brane and the membrane protein CD47 (antiphago-
cytic).49 Angelova et al. studied the impact of TTh on
erythrocytes and found compositional changes in the
cell membrane.34 This change may possibly lead to
lengthening the erythrocyte life span. Around 20% of
Hb is lost from erythrocytes via vesiculation, which
removes damaged membrane constituents.36,50,51 As
this appears to be a gradual process,51 increased life
span would lead to greater Hb loss.
Thus, we can speculate that reduced degradation of
erythrocytes, possibly associated with TTh due to
changes in membrane structure, could result in an in-
creased HCT and increased HCT/Hb ratio, as ob-
served in our analysis. In the event of the above
phenomena, it is important to consider the clinical
implications as increased erythrocyte life span may re-
sult in HbA1c values that do not represent the glyce-
mic status of the patient. The testosterone for diabetes
mellitus (T4DM) RCT showed that TTh (TU) treat-
ment and lifestyle measures in 504 obese/overweight
men with impaired glucose tolerance or newly diag-
nosed T2DM aged 50–74 years over a 24-month pe-
riod (compared with 503 men on placebo and
lifestyle measures) were associated with significantly
lower glucose values (2-h glucose tolerance test).52
Interestingly, however, no difference in HbA1c be-
tween the two study arms was observed. The authors
of the T4DM trial speculated whether increased eryth-
rocyte longevity could have contributed to this find-
ing.52 It must be noted that unlike our longitudinal
study where no man was seen to have an HCT
>52%, 22% (106 men) of the men on TU (1%
(6 men) in the placebo group) had at least a single
HCT ‡54%.52 It must be stated that TU was discontin-
ued in only 23 men due to two HCT values ‡54%.52
Change in Hb has not yet been reported by the
T4DM investigators.
An increase in viscosity associated with higher HCT
is likely to affect blood flow and perfusion.16 This effect
would be dependent on many factors such as erythro-
cyte age, deformability, and morphological changes as-
sociated with glycemic status.16 Thus, the optimal HCT
may vary for the various conditions leading to in-
creased HCT, as they may have differing effects on
the condition of the erythrocyte.
Our longitudinal registry study has strengths and
weaknesses. Compliance was absolute as the TU was
administered in the practice. Follow-up was relatively
long, and data on HCT and Hb were almost complete.
We did not have data on erythrocyte count or estrogen
levels, which could be related to erythrocytosis.53 It
must be emphasized that our findings are perhaps spe-
cific for the cohort studied and TU therapy. The effects
could be different with other testosterone preparations
with varying half-lives.17 Finally, our findings were ob-
servational and did not investigate mechanisms of
TTh-associated erythrocytosis.
Conclusion
In this longitudinal study of 353 men with adult-onset
TD treated with TU, we studied the changes in HCT
and Hb at fixed follow-up time points: 12, 48, 72,
and 96 months. Both HCT and Hb increased at
every time point (c.f. baseline) in the total cohort
and subgroups based on baseline characteristics. Base-
line HCT and Hb levels were inversely associated with
change in HCT and Hb, respectively, at all the time
points studied. At baseline, the HCT/Hb ratio of
3.03 (95% CI: 2.97–3.10) was similar to the expected
value of 3.0. Importantly, the median HCT/Hb ratio
increased in the total cohort and selected subgroups
following TU, with over 90% of the men demonstrat-
ing an increase in value. We suggest that the increase
in the ratio may be due to the increased erythrocyte
life span as speculated by the investigators of the
T4DM study.52 It is essential that the effects of the
TTh-associated changes in HCT, Hb, and HCT/Hb
ratio on outcomes such as erythrocyte life span,
blood flow characteristics such as peak systolic veloc-
ity, CVD, and mortality be evaluated via prospective
studies.16,54
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